References

  1. Jemal A, et al. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43-66.
  2. Bach PB, et al. Computed tomography screening and lung cancer outcomes. JAMA. 2007;297:953-961.
  3. The International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763-1771.
  4. Herth FJ, et al. Endobronchial ultrasound-guided transbronchial needle aspiration. J Bronchol. 2006;13:84-91.
  5. Annema J, et al. Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer. JAMA. 2005;294:931-936.
  6. Yildizeli B, et al. Morbidity, mortality and long term survival after sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;31:95-102.
  7. D'Amico T. Thoracoscopic lobectomy: evolving and improving. J Thorac Cardiovasc Surg. 2006;132:464-465.
  8. Dupuy DE, et al. Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest. 2006;129:738-745.
  9. Pepe C, et al. Adjuvant chemotherapy in elderly patients: an analysis of National Cancer Institute of Canada Trials Group and Intergroup BR. 10. Proc Am Soc Clin Oncol. 2006;24:7009.
  10. Olaussen KA, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991.
  11. Sheperd FA, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123-132.
  12. Lu Y, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006;3:e467.
  13. Bhattacharjee A, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adeno carcinoma subclasses. Proc Natl Acad Sci U S A.
  14. McCloud TC, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182:319-323.
  15. Reed CE, et al. Results of the American College of Surgeons Oncology Group Z0050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943-1951.
  16. Birim O, et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;7 9:375-381.
  17. Lardinois D, et al. Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
  18. Hammoud ZT, et al. The current role of mediastinoscopy in the evaluation of thoracic disease. J Thorac Cardiovasc Surg. 1999;118:894-899.
  19. Park BJ, et al. Management of major hemorrhage during mediastinoscopy. J Thorac Cardiovasc Surg. 2003;126:726-731.
  20. Lemaire A, et al. Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. Ann Thorac Surg. 2006;82:1185-1189.
  21. Little AG, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg. 2005;80:2051-2056.
  22. Herth F, et al. Real-time, endobronchial ultrasound-guided, transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax. 2006;61:795-798.
  23. Cerfolio RJ, et al. Routine mediastinoscopy and esophageal ultrasound fine needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative. Chest. 2006;130:1791-1795.
  24. Larsen SS, et al. Endoscopic ultrasound guided biopsy versus mediastinoscopy for analysis of paratracheal and subcarinal lymph nodes in lung cancer staging. Lung Cancer. 2005;48:85-92.
  25. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
  26. Martini N, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109:120-129.
  27. Ginsberg RJ, et al. Randomized trial of lobectomy versus limited resection for T1N0 non small cell lung cancer. Ann Thorac Surg. 1995;60:615-622.
  28. Keenan RJ, et al. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg. 2004;78:228-233.
  29. Okada M, et al. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132:769-775.
  30. El-Sherif A, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg. 2006;82:408-415.
  31. McKenna RJ Jr, et al. Video-assisted thoracic surgery lobectomy: experience with 1,100 cases. Ann Thorac Surg. 2006;81:421-425.
  32. Onaitis MW, et al. Thoracoscopic lobecto my is a safe and versatile procedure: experience with 500 consecutive patients. Ann Surg. 2006;244:420-425.
  33. Walker WS, et al. Long-term outcomes following VATS lobectomy for non-small cell bronchogenic carcinoma. Eur J Cardiothorac Surg. 2003;23:397-340.
  34. Nagahiro I, et al. Pulmonary function, postoperative pain, and serum cytokine level after lobectomy: a comparison of VATS and conventional procedure. Ann Thorac Surg. 2001;72:362-365.
  35. Suguira H, et al. Long-term benefits for the quality of life after video-assisted thoracscopic lobectomy in patients with lung cancer. Surg Laparosc Endosc. 1999;9:403- 410.
  36. Landreneau RJ, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113:691-698.
  37. Steinke K, et al. Pulmonary radiofrequency ablation: an international study survey. Anticancer Res. 2004;24:339-343.
  38. Gandhi NS, et al. Image-guided radiofrequency ablation as a new treatment option for patients with lung cancer. Semin Roentgenol. 2005;40:171-181.
  39. Rowell NP, et al. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax. 2001;56:628-638.
  40. Bradley JD, et al. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys. 2003;56:342-347.
  41. McGarry RC, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:10101015.
  42. Onishi H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: clinical oucomes in 245 subjects in a Japanese multi institutional study. Cancer. 2004;101:16231631.
  43. Timmerman R, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833-4839.
  44. Strauss GM, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ib non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. In: Program and abstracts of the 40th American Society of Clinical Oncology (ASCO) Annual Meeting; June 5-8, 2004; New Orleans, LA. Abstract 7019.
  45. Okada M, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129:87-93.
  46. Lee W, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg. 2003;75:237-242.
  47. Arriagada R, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
  48. Winton T, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597
  49. Douillard JY, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727.
  50. Scagliotti GV, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003;95:1453-1461.
  51. Waller D, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173-182.
  52. Pignon JP, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol. 2006;24:366s. Abstract 7008.
  53. National Comprehensive Cancer Network NCCN): Practice Guidelines in OncologyTM- v.1.2007 Non-small cell lung cancer. http://www.nccn.org.
  54. Strauss GM, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2006;24:365s. Abstract 7007.
  55. Wakelee HA, et al. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer. 2006;8:18-21.
  56. Hotta K, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852-3859.
  57. Ardizzoni A, et al. CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2006;24:366s. Abstract 7011.
  58. Rosell R, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial [see comments]. Lung Cancer. 1999;26:7-14.
  59. Roth JA, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1-6.
  60. Martini N, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993;55:1365-1373; discussion 1373-1374.
  61. Depierre A, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247-253.
  62. Pisters KM, et al. S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol. 2005;23:624s. Abstract LBA7012.
  63. 63.Travis WD, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization Pathologic Criteria. J Thorac Oncol. 2006;1:S13-S19.
  64. Rusch V, et al. Surgery for bronchioloalveolar carcinoma and "very early"adenocarcinoma: an evolving standard of care. J Thorac Oncol. 2006;1:S27-S31.
  65. Terasaki H, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27:937-951.
  66. Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542-2550.
  67. Hanahan D, et al. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
  68. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-18.
  69. Strauss GM, et al. Adjuvant chemotherapy in stage IB NSCLC: update of CALGB 9633. J Clin Oncol Proc. 2006:24(suppl):7007.
  70. Fukuoka M, et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
  71. Kris MG, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA. 2003;290:2149-2158.
  72. Thatcher N, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
  73. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
  74. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
  75. Kelly K, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol. 2005;23:7058.
  76. Tsuboi M, et al. Gefitinib in the adjuvant setting: safety results from a Phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs. 2005;16:1123-1128.
  77. Gibbons DL, et al. Epidermal growth factor receptor inhibitors: moving from advanced into early stage lung cancer. Adv Lung Cancer. 2006;7:8-11.
  78. Kris M, et al. Prospective trial with pre-operative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. J Clin Oncol. 2006;24:7021.
  79. Raponi M, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006;66:7466-7472.
  80. Potti A, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355:570-580.
  81. Chen HY, et al. A five-gene signature and clinical outcomes in non-small cell lung cancer. N Engl J Med. 2007;356:11-20. 2001;98:13790-13795.
  82. Beer DG, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816-824.
  83. Wigle DA, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002;62:3005-3008.
  84. Kikuchi T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003; 22:2192-2205.
  85. Garber ME, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;98:13784-13789.
  86. Zheng Z, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800-808.
  87. Bepler G, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006;24:4731-437.
  88. Potti A, et al. A genomic strategy to direct use of targeted therapeutic drugs in advanced stage non-small cell lung carcinoma. Nat Med. 2006;12:1294-1300.
  89. Bild A, et al. Signatures of oncogenic pathway deregulation in human cancers. Nature. 2005;439:353-357.

^ Back to top